Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs (COMPARE-AT)
Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study
연구 개요
상태
정황
상세 설명
This study is a single-center, randomized, open-label, active-comparator trial designed to characterize the differential effects of tirzepatide and semaglutide on adipose tissue biology and cardiometabolic remodeling over 12 months in adults with obesity and metabolic syndrome. The trial integrates pharmacologic weight-loss therapy with multimodal phenotyping to quantify changes across body composition, hepatic steatosis, metabolic biomarkers, functional strength, and AI-derived electrophysiologic signatures.
The scientific premise is that incretin-based therapies may produce qualitatively distinct patterns of fat loss, ectopic fat mobilization, and cardiometabolic improvement. Tirzepatide, a dual GIP/GLP-1 receptor agonist, may induce greater reductions in visceral adiposity and hepatic fat compared with GLP-1 receptor agonism alone. This trial is designed to directly compare these mechanistic profiles using harmonized imaging, biochemical, and digital phenotyping platforms.
Participants are randomized 1:1 to tirzepatide or semaglutide using a computer-generated permuted block scheme stratified by sex and baseline BMI category. Both interventions follow standard titration schedules and are paired with structured lifestyle counseling to ensure comparable background care. Study visits occur at baseline, 3, 6, and 12 months, with deep phenotyping at baseline, 6, and 12 months.
The phenotyping framework emphasizes regional adiposity, lean mass preservation, hepatic steatosis, and cardiometabolic risk signatures. Whole-body DXA provides quantification of total and regional fat and lean mass, enabling derivation of fat-to-lean mass loss ratios and redistribution indices. Abdominal MRI with proton density fat fraction (PDFF) quantifies liver fat content and abdominal fat compartments. Functional and behavioral assessments-including grip strength and the Chinese version of the Weight-Related Eating Questionnaire-characterize changes in physical function and eating behavior patterns over time.
Fasting biochemical panels measure glycemic indices, lipid metabolism, inflammation, renal and hepatic function, and cardiometabolic biomarkers. Standard 12-lead ECGs are processed through a validated AI pipeline to generate electrophysiologic risk features (e.g., predicted ASCVD risk, ECG-derived heart age), which serve as exploratory digital biomarkers.
A centralized biobanking program supports mechanistic analyses. Serum, plasma, and PBMCs collected at each deep-phenotyping visit are stored under standardized SOPs for targeted and discovery-based metabolomic, proteomic, epigenetic and transcriptomic analyses. These biospecimens will enable downstream investigation of molecular pathways underlying differential treatment responses.
Together, this integrated platform allows for a comprehensive comparison of tirzepatide and semaglutide across structural, metabolic, functional, and molecular domains, providing mechanistic insight into how incretin-based therapies remodel adipose tissue and cardiometabolic physiology.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Feng-Chih Kuo, M.D., Ph.D.
- 전화번호: 12687 886-2-87923311
- 이메일: shoummie@hotmail.com
연구 장소
-
-
-
Taipei, 대만, 114202
- 모병
- Tri-Service General Hospital
-
연락하다:
- Feng-Chih Kuo, M.D., Ph.D.
- 전화번호: 12687 886-2-87923311
- 이메일: shoummie@hotmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age 20-65 years.
- BMI ≥27 kg/m² with metabolic syndrome (ATP III or IDF criteria).
- Stable background medications (antihypertensives, statins, etc.) for ≥3 months.
- Able and willing to provide informed consent and comply with study procedures.
Exclusion Criteria:
- History of diabetes; history of pancreatitis; personal/family history of medullary thyroid carcinoma or MEN2.
- eGFR <30 mL/min/1.73 m², decompensated liver disease, NYHA class III-IV heart failure.
- Recent (<3 months) acute coronary syndrome, stroke, or coronary revascularization.
- Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months.
- Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Tirzepatide arm
starting at 2.5 mg weekly and escalated every month (5.0 mg, 7.5 mg to 10 mg) as tolerated
|
Starting at Tirzepatide 2.5 mg weekly and escalated as tolerated to 10 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.
|
|
활성 비교기: Semaglutide arm
starting at 0.25 mg weekly and escalated every month (0.5 mg, 1.0 mg, 1.7 mg to 2.4 mg) as tolerated
|
Starting at Semaglutide 0.25 mg weekly and escalated as tolerated to 2.4 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percent change in total body weight from baseline to 6 months.
기간: Baseline to 6 months
|
Baseline to 6 months
|
|
Total fat to lean mass loss ratio (DXA derived) from baseline to 6 months.
기간: Baseline to 6 months
|
Baseline to 6 months
|
|
Change in metabolic syndrome severity Z score from baseline to 6 months.
기간: Baseline to 6 months.
|
Baseline to 6 months.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in waist circumference (cm)
기간: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in waist-to-hip ratio (unitless ratio)
기간: Baseline to 6 months and 12 months.
|
Baseline to 6 months and 12 months.
|
|
|
Change in regional fat mass measured by DXA (grams)
기간: Baseline to 6 months and 12 months.
|
Baseline to 6 months and 12 months.
|
|
|
Change in regional lean mass measured by DXA (grams)
기간: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in 7-site skinfold thickness (mm)
기간: Baseline to 6 months and 12 months.
|
Baseline to 6 months and 12 months.
|
|
|
Change in liver fat content measured by MRI-PDFF (percentage, %PDFF)
기간: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in abdominal visceral fat volume (mL)
기간: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in abdominal subcutaneous fat volume (mL)
기간: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in systolic and diastolic blood pressure (mmHg)
기간: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in fasting lipid profile (mg/dL)
기간: Baseline to 6 months and 12 months
|
Lipid profile includes total cholesterol, LDL-C, HDL-C and Triglycerides
|
Baseline to 6 months and 12 months
|
|
Change in fasting glucose (mg/dL)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in hsCRP (mg/L)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in insulin sensitivity (HOMA-IR, unitless)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in β-cell function (HOMA-β, percentage, %)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in AI-ECG predicted ASCVD risk score (percentage, %)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in ECG-derived heart age (years)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in AI-ECG diabetes risk index (HbA1c, percentage, %)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in estimated 10-year ASCVD risk (percentage, %)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in bone mineral density (g/cm²)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in serum P1NP (ng/mL)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in serum CTX-1 (ng/mL)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in fasting plasma metabolomics profile (relative abundance units)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in fasting plasma proteomics profile (relative abundance units)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in microRNA expression signatures (normalized expression units)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in RNA-seq transcriptomic signatures (normalized counts, e.g., TPM)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in epigenetic methylation signatures (Methylation, percentage, %)
기간: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in depressive symptoms (scale score)
기간: Baseline to 6 and 12 months
|
Instrument: e.g., PHQ-9
|
Baseline to 6 and 12 months
|
|
Change in sleep quality (scale score)
기간: Baseline to 6 and 12 months
|
Instrument: e.g., PSQI
|
Baseline to 6 and 12 months
|
|
Change in quality of life (scale score)
기간: Baseline to 6 and 12 months
|
Instrument: e.g., EQ-5D or SF-36
|
Baseline to 6 and 12 months
|
|
Change in eating behavior (WREQ-C total and subscale scores)
기간: Baseline to 3, 6, and 12 months
|
Baseline to 3, 6, and 12 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Feng-Chih Kuo, M.D., Ph.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- C202505161
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .